Davern Capital Partners »

Eli Lilly & Co. shares owned by Davern Capital Partners

Quarter-by-quarter ownership of Eli Lilly & Co. (LLY) shares owned by Davern Capital Partners from 13F filings

Historical chart of Davern Capital Partners investment in Eli Lilly & Co.

Tip: Access up to 7 years of quarterly data

All positions including Eli Lilly & Co. held by Davern Capital Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Eli Lilly & Co. by Davern Capital Partners

Quarter filed Position value Share count Share price at filing
2025-12-31 $8.9M 8.3k 1074.68

More positions owned by Davern Capital Partners

Pfizer (PFE)
Regeneron Pharmaceuticals (REGN)
Biontech Se Sponsored Ads (BNTX)
Royalty Pharma Shs Class A (RPRX)
Argenx Se Sponsored Adr (ARGX)
Legend Biotech Corp Sponsored Ads (LEGN)
Roivant Sciences SHS (ROIV)
Ionis Pharmaceuticals (IONS)
Natera (NTRA)
Eli Lilly & Co. (LLY)
Miragen Therapeutics (VRDN)
Mineralys Therapeutics (MLYS)
Cg Oncology (CGON)
Abivax Sa Sponsored Ads (ABVX)

View all positions for Davern Capital Partners

Top funds holding Eli Lilly & Co.

Lilly Endowment
Vanguard Group
BlackRock
Pnc Financial Services
State Street Corporation
Capital Research Global Investors
FMR
Geode Capital Management
Capital World Investors
Wellington Management Company
State Farm Mutual Automobile Insurance Company
PRIMECAP Management Company
Jpmorgan Chase & Co
Capital Research and Management Company - Division 3
Northern Trust

View all funds holding Eli Lilly & Co.